US54300N1037 - Common Stock
LONGBOARD PHARMACEUTICALS IN
NASDAQ:LBPH (3/28/2024, 12:27:45 PM)
21.43
+0.45 (+2.14%)
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company is headquartered in La Jolla, California and currently employs 33 full-time employees. The company went IPO on 2021-03-12. The company is focused on developing medicines for neurological diseases. Its pipeline includes LP352 and LP659. LP352 is an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, Lennox-Gastaut syndrome, CDKL5 deficiency disorder, SCN2A-related disorders, among others. LP659 is a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator for inflammatory neurological conditions. LP659 is designed to avoid the negative effects connected to the receptor subtypes 2 and 3, which is associated with serious, off-target cardiac, pulmonary, and cancer-related effects. The company also has license to certain compounds including LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, and compounds targeting the 5-HT2A receptor, including nelotanserin.
LONGBOARD PHARMACEUTICALS IN
4275 Executive Square, Suite 950
La Jolla CALIFORNIA 92121
P: 16195929775
CEO: Kevin R. Lind
Employees: 33
Website: https://www.longboardpharma.com/
Longboard Pharmaceuticals (LBPH) shares were up 8% Friday after Citigroup initiated coverage of the stock with a buy rating, citing its potential as a takeover
Here you can normally see the latest stock twits on LBPH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: